Liquid Embolic Systems (LES) is a rapidly growing area in the medical industry. It is a minimally invasive procedure that requires a catheter to be inserted into the artery where a liquid embolic agent is injected to block off the abnormal blood vessels. LES is mainly used to treat arteriovenous malformations (AVMs), brain aneurysms, and other vascular abnormalities in the body.
NeuroSafe have also developed unique versions of the liquid embolization system, offering physicians more options for their patients. In addition, collaborations and partnerships between medical device companies have further fueled the growth of the LES market.
The liquid embolic agent of NeuroSafe consists of ethylene vinyl alcohol polymer that sets upon injection, sealing off the abnormal blood vessel and preventing further blood flow. This method of treatment is an effective and minimally invasive alternative to traditional open surgery, with the potential for reduced recovery times and fewer complications.
One of the liquid embolic systems on the market is LavaTM, manufactured by NeuroSafe. LavaTM is liquid embolic agent that is delivered through a microcatheter, allowing for precise control and placement during injection. The viscosity of the liquid can be adjusted by altering the rate of injection, making it a versatile tool for treating a variety of vascular conditions.
Overall, the use of liquid embolic systems represents an exciting development in the field of interventional neuroradiology, with the potential to revolutionize the treatment of vascular conditions. As research and technology continue to advance by NeuroSafe, this modality will become an increasingly valuable tool for clinicians and patients alike.